VERTEX PHARMACEUTICALS INC / MA
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $12.0B | $11.0B | $9.9B | $8.9B | $7.6B |
| Cost of revenue | $1.7B | $1.5B | $1.3B | $1.1B | $904.2M |
| Selling, general & administrative | $1.8B | $1.5B | $1.1B | $944.7M | $840.1M |
| Research and development | $3.9B | $3.6B | $3.2B | $2.5B | $3.1B |
| Operating income | $4.2B | -$232.9M | $3.8B | $4.3B | $2.8B |
| Interest expense | $13.3M | $30.6M | $44.1M | $54.8M | — |
| Pretax income | $4.6B | $248.5M | $4.4B | $4.2B | $2.7B |
| Income tax expense | $690.0M | $784.1M | $760.2M | $910.4M | $388.3M |
| Net income | $4.0B | -$535.6M | $3.6B | $3.3B | $2.3B |
| Balance Sheet | |||||
| Cash and equivalents | $5.1B | $4.6B | $10.4B | $10.5B | $6.8B |
| Current assets | $11.2B | $9.6B | $14.1B | $13.2B | $9.6B |
| Total assets | $25.6B | $22.5B | $22.7B | $18.2B | $13.4B |
| Current liabilities | $3.9B | $3.6B | $3.5B | $2.7B | $2.1B |
| Total liabilities | $7.0B | $6.1B | $5.1B | $4.2B | $3.3B |
| Stockholders' equity | $18.7B | $16.4B | $17.6B | $13.9B | $10.1B |
| Cash Flow Statement | |||||
| Cash from operations | $3.6B | -$492.6M | $3.5B | $4.1B | $2.6B |
| Depreciation and amortization | $209.8M | $207.2M | $181.3M | $148.3M | $125.6M |
| Stock-based compensation | $685.9M | $698.5M | $581.2M | $491.3M | $441.4M |
| Capital expenditure | $437.6M | $297.7M | $200.4M | $204.7M | $235.0M |
| Free cash flow | $3.2B | -$790.3M | $3.3B | $3.9B | $2.4B |
| Share repurchases | $2.0B | $1.2B | $427.6M | $0 | $1.4B |
| Impairments | $379.0M | $0 | $0 | — | — |
Shares outstanding 253.8M · Free float 99.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.